A Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel® (Oral Paclitaxel) Compared to Taxol® (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic Breast Cancer
Phase of Trial: Phase II/III
Latest Information Update: 12 Jun 2018
At a glance
- Drugs Paclitaxel (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms OPTIMAL
- Sponsors Daehwa Pharmaceutical
- 04 Jun 2018 Planned number of patients changed from 510 to 476.
- 04 Jun 2018 Planned End Date changed from 31 Oct 2021 to 31 Mar 2022.
- 04 Jun 2018 Planned primary completion date changed from 31 Oct 2018 to 31 Jan 2019.